Everything we referenced in our note to you, in one place. No forms, no gate — read, watch, and if it's relevant to how you run quality, book twenty minutes with our founder.
Two editions, one argument: GMP-critical decisions demand deterministic, explainable analysis — and the audit trail to prove it. Ungated, no email required.
Starts from FY2025 483 reality — the citation categories inspectors actually write — and walks a dual-layer AI architecture through Part 11, FDA's final CSA guidance, PCCP, and the agency's emerging AI-credibility expectations. Section 7 is not a roadmap: it describes the batch-release workflow, Part 11-designed e-signatures, and agent-attributed audit trail running in the platform today.
Read the US editionThe EU is drafting the first dedicated GMP guideline for AI. This edition reads the draft text closely — what it would permit, what it would prohibit, and why human-in-the-loop oversight alone doesn't answer the architecture question. For quality leaders operating under EMA inspection and planning EU AI Act obligations.
Request the EU edition (final review)Warning Letter 320-26-58: a manufacturer let consumer AI author specifications, SOPs, and master production records with no Quality Unit review — and FDA cited it under 21 CFR 211.22(c). Our teardown maps each finding to the control that prevents it. FDA's message wasn't "don't use AI." It was: AI output without Quality Unit sign-off is a cGMP deficiency.
Request the teardownEvery control in the teardown — named human approver, Part 11 e-signature before effectiveness, agent-attributed audit trail — is the shipped workflow the white papers describe in Section 7. Same architecture, seen from the enforcement side.
Joe Ryan built NexGen to answer one question: how do you put AI into a quality system you'll have to defend? Bring your hardest inspection scenario — that's the conversation he wants to have.
Book a call with JoePrefer email? joe@nexgengxp.com